B
Bull
Bull · 25%ZURA
$2.23
Szenariopreis
$5.720
-0.127 (-2.22%)Zum Schluss
Loading chart…
- High
- 5.890
- Open
- 5.880
- VWAP
- 5.70
- Vol
- 1.89M
- Mkt Cap
- 214.61M
- Low
- 5.490
- Amount
- 10.79M
- EV/EBITDA, TTM
- 0.00
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
AI analysis of Zura Bio Ltd (ZURA)
buyZura Bio Ltd is a good buy right now due to its current price of $5.72, which is significantly below the average analyst price target of $15.86. Additionally, the stock has shown a remarkable 183.17% increase over the past year, indicating strong historical performance. However, the company is facing ongoing losses, with a net income of -$24,223,000 reported for Q1 2026, which remains a key risk to consider.
Bewertungskennzahlen
The current forward P/E ratio for Zura Bio Ltd (ZURA) is 0.00, compared to its 5-year average forward P/E of -4.61.
Alphio AI Price Scenarios for ZURA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ZURA
Event-Zeitleiste
News
5.008-22NewsfilterZura Bio Grants Stock Options to New Employees
5.006-30NASDAQ.COMTenaya Therapeutics Appoints New CFO Eric Hyllengren
- 8.506-29Newsfilter
Zura Bio Updates on Tibulizumab Clinical Progress
- 5.005-14Newsfilter
Zura Bio Grants Stock Options to New CBO
- 5.005-13Newsfilter
Zura Bio Appoints New Chief Business Officer
ZURA FAQ — answered by Alphio AI
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Zura Bio Ltd is a good buy right now due to its current price of $5.72, which is significantly below the average analyst price target of $15.86. Additionally, the stock has shown a remarkable 183.17% increase over the past year, indicating strong historical performance. However, the company is facing ongoing losses, with a net income of -$24,223,000 reported for Q1 2026, which remains a key risk to consider.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.